Skip to main content
. 2018 Jul 6;57(23):3365–3370. doi: 10.2169/internalmedicine.1113-18

Table 1.

Clinical Characteristics.

Case Mutation Predominant phenotype Sex Age at examination (years) Duration of neuropathy (years) Initial symptom of neuropathy Modified Rankin scale* Cardiac findings
CTR** (%) EF*** (%) IVS*** thickness (mm) E/e’ Plasma BNP (pg/mL)
1 Val94Gly Neuropathy F 51 2 P in UE 2 51 61 11.6 11.9 56.1
2 Val71Ala Neuropathy F 35 4 P in LE 4 38 74 7.5 ND ND
3 Pro24Ser Neuropathy M 75 5 P in LE 2 44 62 13.1 14.6 56.7
4 Thr60Ala Cardiomyopathy M 64 1 P in LE 1 52 39 15.2 21.1 89.2****
5 Tyr114Cys Oculolepto-meningeal M 43 4 P in LE 3 36 66 9.5 9.9 55.8

CTR: cardiothoracic ratio, EF: ejection fraction, IVS: interventricular septum, LE: lower extremities, ND: not determined, P: paraesthesia or pain, UE: upper extremities

*According to a previous report (15): 0=no symptoms at all; 1=no significant disability despite the presence of symptoms, demonstrated as the ability to perform all typical duties and activities; 2=slight disability, demonstrated as the inability to perform all previous activities but the ability to perform self-care without assistance; 3=moderate disability, demonstrated as requiring some help but being able to walk without assistance; 4=moderately severe disability, demonstrated as the inability to walk without assistance and to attend to bodily needs without assistance; and 5=severe disability, demonstrated as being bedridden and incontinent and requiring constant nursing care and attention.

**Assessed by chest X-ray

***Assessed by two-dimensional and M-mode echocardiography

****Diuretic agents were administered.

The normal values for CTR, EF, IVS thickness, E/e’ and plasma BNP are ≤50%, >60%, ≤ 11 mm, ≤8, and ≤ 20 pg/mL, respectively.